Post links GLP-1 drugs to lower cancer risk
- On May 21, physician account Transplant_Doc highlighted research linking GLP-1 drugs to lower cancer risk or slower progression and called for larger trials. - The clearest recent data point came from Cleveland Clinic research: lung cancer patients taking GLP-1 drugs were 50% less likely to progress. - The next test comes at ASCO’s May 29-June 2 meeting in Chicago, where researchers including Mark Orland are presenting new analyses.
A May 21 social media thread from physician account Transplant_Doc pointed readers to a growing cluster of studies linking GLP-1 drugs with lower cancer risk or slower cancer progression. The post did not report a clinical trial result of its own. It summarized observational findings and called for larger, controlled studies to test whether the association holds over several years. Recent data give that argument fresh material. Cleveland Clinic researchers reported this week that patients with some early-stage cancers who started a GLP-1 drug after diagnosis were less likely to progress to metastatic disease than similar patients who took a DPP-4 inhibitor instead. A separate 2025 JAMA Oncology study found lower overall cancer risk among adults with obesity who took GLP-1 receptor agonists, compared with matched nonusers. ### Which studies are driving the new discussion? A May 22, 2025 ASCO press release described a large observational study of 170,030 U.S. adults with diabetes and obesity. In that analysis, GLP-1 receptor agonists were associated with a modestly lower risk of 14 obesity-related cancers, especially colorectal cancer, when compared with DPP-4 inhibitors. ASCO said the study did not establish causation. (nbcnews.com) A 2025 JAMA Oncology paper examined electronic health record data from OneFlorida+ covering 2014 to 2024. The study compared 43,317 adults with obesity taking GLP-1 receptor agonists with 43,315 matched nonusers and found a significant association with reduced overall cancer risk, with signals that were stronger for endometrial, meningioma and ovarian cancers. The authors also reported a nonsignificant increased risk signal for kidney cancer and said long-term follow-up is needed. (asco.org) ### What did the newer cancer-progression study find? NBC News reported on May 21 that Dr. Mark Orland of Cleveland Clinic led a study using the TriNetX Global Health Research Network database. The researchers identified more than 10,000 patients with stage 1, 2 or 3 breast, colorectal, kidney, liver, lung, pancreatic or prostate cancer who began taking a GLP-1 drug after diagnosis. (jamanetwork.com) In that analysis, patients taking GLP-1 drugs were less likely to have metastatic progression in every cancer type except kidney cancer, NBC reported. The reduction reached statistical significance in four cancers: non-small cell lung, breast, colorectal and liver. Lung cancer patients taking GLP-1 drugs were 50% less likely to progress to stage 4 than matched patients taking a DPP-4 inhibitor, while breast cancer patients were 43% less likely to progress, according to the report. (nbcnews.com) ### Why are researchers being careful about the claim? The Cleveland Clinic analysis was observational and had not yet been published in a peer-reviewed journal as of May 21, NBC reported. That means the study can show an association, but it cannot prove the drugs themselves caused the lower rate of progression. Robin Zon, then ASCO president, used similar language when discussing the earlier cancer-incidence study. (nbcnews.com) Zon said the research raised “an intriguing hypothesis” that GLP-1 medicines “might offer some benefit” in reducing cancer risk, but added that future research is needed to validate the findings, including in patients without diabetes. ### What is the main limitation readers should keep in mind? GLP-1 drugs are approved for diabetes and, in some cases, obesity, not for cancer prevention. Columbia University’s cancer center said earlier this year that GLP-1 weight-loss drugs are not cancer-prevention medicines and that current evidence is still early, even as it called the data increasingly reassuring. (asco.org) The next concrete milestone is the 2026 American Society of Clinical Oncology annual meeting in Chicago from May 29 to June 2, where Orland’s team is scheduled to present the progression data. Larger randomized trials would be needed to determine whether GLP-1 drugs directly reduce cancer incidence or slow spread in specific tumors. (managedhealthcareexecutive.com) (cancer.columbia.edu)
